Pura Lukman, Putri Raeni Dwi, Prahmana Muh Arya, Wijaya Muhammad Palar, Bandiara Ria, Faried Ahmad, Supriyadi Rudi
Doctoral Study Program of Medical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40132, Indonesia.
Dr. H. Abdul Moeloek Regional General Hospital, Bandar Lampung 35112, Indonesia.
Cells. 2025 Aug 24;14(17):1313. doi: 10.3390/cells14171313.
Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.
Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.
Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = -155.80; 95% CI: -249.10, -62.51; = 0.001) and tumor necrosis factor-α (TNF-α) (MD = -35.53; 95% CI: -52.75, -18.30; < 0.0001). In patients, TNF-α reduction was not significant (MD = -0.74; 95% CI: -2.20, 0.73; = 0.32). Serum creatinine decreased in animals (MD = -0.38; 95% CI: -0.46, -0.29; < 0.00001), but not in patients (MD = -0.59; 95% CI: -1.92, 0.74; = 0.39). Blood urea nitrogen decreased in animals (MD = -19.27; 95% CI: -23.50, -15.04; < 0.00001), and glomerular filtration rate improved (standardized MD = 1.83; 95% CI: 0.51, 3.15; = 0.007), with no change in patients.
MSCs improve inflammation and renal function in CKD animal models; however, evidence in patients remains inconclusive.
慢性肾脏病（CKD）很大程度上由炎症驱动。间充质干细胞（MSCs）显示出治疗潜力；然而，其在不同CKD病因中的疗效仍不明确。
在PubMed、Cochrane、ScienceDirect、Scopus和谷歌学术中进行全面检索。对炎症和肾功能结局的效应量进行荟萃分析。
在筛选的2514项研究中，52项符合纳入标准（49项动物研究，3项随机对照试验）。在动物模型中，MSCs显著降低白细胞介素-6（平均差[MD]= -155.80；95%可信区间：-249.10，-62.51；P = 0.001）和肿瘤坏死因子-α（TNF-α）（MD = -35.53；95%可信区间：-52.75，-18.30；P < 0.0001）。在患者中，TNF-α降低不显著（MD = -0.74；95%可信区间：-2.20，0.73；P = 0.32）。动物血清肌酐下降（MD = -0.38；95%可信区间：-0.46，-0.29；P < 0.00001），但患者中未下降（MD = -0.59；95%可信区间：-1.92，0.74；P = 0.39）。动物血尿素氮下降（MD = -19.27；95%可信区间：-23.50，-15.04；P < 0.00001），肾小球滤过率改善（标准化MD = 1.83；95%可信区间：0.51，3.15；P = 0.007），患者中无变化。
MSCs可改善CKD动物模型中的炎症和肾功能；然而，患者中的证据仍不确凿。
